All News

Found 5,710 articles

• AppliedVR Announces Results from a Clinical Trial Follow-up Study Finding RelieVRx Delivers Durable Effects Six Months After Completing Treatment

  7/21/2022

  AppliedVR today announced the results from a follow-up study that analyzed the durable effects of its flagship product, RelieVRx, which was recently granted marketing authorization by the FDA for chronic low back pain (CLBP).

• Endonovo Therapeutics Releases A Comparative Analysis Addressing Limitations Of Non-Opioid Pharmaceutical Interventions on the Reduction of Opioid/Narcotic Use For Post-Surgical Pain Management

  7/21/2022

  Endonovo Therapeutics Inc. (OTCQB:ENDV) today released a comparative analysis detailing how its SofPulse® medical device out-performed all pharmaceutical competitors non-opioid alternatives for surgical pain management.

• Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F

  7/21/2022

  RELIEF THERAPEUTICS Holding SA announced that the U.S. Securities and Exchange Commission has declared effective its Registration Statement on Form 20-F.

• Gallium-68 Market to grow at a CAGR of 8% from 2021 to 2030

  7/21/2022

  The global gallium-68 market is projected to reach US$ 200 Mn by 2030, expanding at a CAGR of 8% from 2021 to 2030.

• Yuyu Pharma Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating YP-P10 Ophthalmic Solution for the Treatment of Dry Eye Disease

  7/20/2022

  Yuyu Pharma announces the enrollment of the first patient in a phase 2 clinical study evaluating YP-P10, a novel and patented synthetic peptide with anti-inflammatory and wound healing properties to treat patients with dry eye disease (DED).

• Interstitial Cystitis Market Growth by 2030: Increasing Prevalence of Autoimmune Diseases and Rising Women Population Across the Globe is a major factor Driving Industry Revenue Growth

  7/20/2022

  Forecast to 2030,’ thoroughly examines the Interstitial Cystitis industry to provide essential data & information for the targeted readers.

• New Study of Aerin Medical’s RhinAer® Shows Positive Clinical and Quality-of-Life Results Following Treatment for Chronic Rhinitis

  7/19/2022

  Aerin Medical Inc., a company that provides Ear, Nose and Throat (ENT) physicians with non-invasive solutions to treat chronic nasal conditions, today announced the publication of positive results from the RELIEF clinical trial in the American Journal of Rhinology & Allergy.

• Stuart Therapeutics Announces Successful Outcome from Type C Meeting with FDA

  7/18/2022

  Stuart Therapeutics, Inc.  ( Stuart ), a clinical stage company headquartered in Stuart, Florida that is developing advanced ophthalmic therapeutics, announced today the results of its Type C Guidance meeting with the U.S. Food and Drug Administration (FDA) regarding the continued development plan for ST-100.

• Zomedica Acquires Assets of Leading tPEM(TM) Company Assisi Animal Health

  7/18/2022

  Zomedica Corp., a veterinary health company offering diagnostic and therapeutic products for companion animals, announced that it had acquired substantially all the assets of Assisi Animal Health LLC.

• Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (Sodium Phenylbutyrate) New Drug Application (NDA) to the FDA for the Treatment of Urea Cycle Disorders (UCDs)

  7/18/2022

  RELIEF THERAPEUTICS Holding SA, announced that its collaboration partner, ACER Therapeutics, Inc., for ACER-001 for oral suspension for the treatment of patients with urea cycle disorders, has resubmitted its New Drug Application for ACER-001 to the U.S. Food and Drug Administration.

• Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine

  7/18/2022

  RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, announced the appointment of Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine, effective July 18, 2022.

• Preclinical Data Demonstrate Potential of Creative Bio-Peptides’ Multi-Chemokine Receptor Antagonist RAP-103 to Provide Opioid Sparing Post-Surgical Pain Relief and Treatment for Chronic Pain

  7/14/2022

  Creative Bio-Peptides, Inc, a preclinical-stage biotechnology company developing novel therapies to balance the innate immune system and promote regeneration of damaged neurons, today announced the publication of findings from a preclinical study showing that treatment with the small oral peptide chemokine receptor antagonist RAP-103.

• SPR Therapeutics to Present Clinical Trial and Real-World Findings at ASPN 2022

  7/14/2022

  SPR Therapeutics announced today that two presentations highlighting SPRINT® PNS in treating chronic pain will be featured at the American Society of Pain & Neuroscience (ASPN) conference July 14-17.

• PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson’s Disease and Motor Disorders

  7/13/2022

  PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, announced today that the United States Patent and Trademark Office (“USPTO”) has provided a Notice of Allowance for patent application No. 15/574,346, titled “Compositions and Methods for Treating Motor Disorders”, which includes claims intended to cover ketamine in the potential treatment of Parkinson’s Disease.

• Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU

  7/13/2022

  RELIEF THERAPEUTICS Holding SA announced that its wholly owned subsidiary, APR Applied Pharma Research SA, has executed a definitive agreement with Meta Healthcare Ltd., acquiring the worldwide rights, except for the United Kingdom, for a novel dosage form of a prescription drug already approved by the U.S.

• Opioid Pain Therapeutics Market: Technological Advancement and New Product Lunch to Drive the Market

  7/13/2022

  Wilmington, Delaware, United States, Transparency Market Research Inc.: Potent pain reducing medications made with compounds such as morphine, hydrocodone, codeine, methadone, and oxycodone fall under the category of opioid drugs.

• U.S. Topical Pain Relief Market Size to Worth Around US$ 3,472 Mn by 2030

  7/13/2022

  According to Nova One Advisor, The U.S. Topical Pain Relief market size was valued at US$ 2,812 million in 2021 and is expected to hit US$ 3,472 million by 2030, growing at a compound annual growth rate (CAGR) of 4.7% from 2022 to 2030.

• U.S. Pain Management Drugs Market Size to Surpass US$ 40.25 BN By 2030

  7/13/2022

  The U.S. Pain Management Drugs market size was valued at US$ 31.52 billion in 2021 and is expected to hit US$ 40.25 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.10% from 2022 to 2030.

• 

  Aldeyra Scores Late-Stage Clinical Win in Competitive Dry Eye Space

  7/12/2022

  Aldeyra Therapeutics announced results from a crossover clinical trial, showing that its drug candidate reproxalap was effective in improving ocular redness and tear production in patients with dry eye disease.

• VisionHealth and Boehringer Ingelheim: Digital therapy support for asthma and COPD

  7/12/2022

  VisionHealth and Boehringer Ingelheim will cooperate on the Kata® app for therapy support in asthma and chronic obstructive pulmonary disease (COPD).